Last reviewed · How we verify

NCT02064634

A Multicenter, Comparative, Open Label, Prospective Observational Study on Discontinuation of Medication Due to Gastrointestinal Adverse Effects for the Patients Being Treated for Osteoarthritis With Anti-inflammatory Analgesic Drug

Status unknown Last updated 15 March 2016
What this trial tests

trial in Osteoarthritis in 6,700 participants. Status unknown.

Timeline
1 May 2014
Primary endpoint
1 June 2016
1 December 2016

Quick facts

Lead sponsorGreen Cross Corporation
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment6,700
Start date1 May 2014
Primary completion1 June 2016
Estimated completion1 December 2016
Sites1 location across South Korea

Conditions studied

Sponsor

Green Cross Corporation — full company profile →

Who can join

20 and older, any sex, with Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

This study investigates how gastrointestinal toxicity affects discontinuation of medication given to patients with osteoarthritis in routine clinical practice.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Osteoarthritis

Currently open trials in the same condition.

Other Green Cross Corporation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02064634.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing